Intervention Review

You have free access to this content

Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease

  1. Raffi Lev-Tzion1,*,
  2. Anne Marie Griffiths2,
  3. Oren Ledder1,
  4. Dan Turner1

Editorial Group: Cochrane IBD Group

Published Online: 28 FEB 2014

Assessed as up-to-date: 22 NOV 2013

DOI: 10.1002/14651858.CD006320.pub4


How to Cite

Lev-Tzion R, Griffiths AM, Ledder O, Turner D. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD006320. DOI: 10.1002/14651858.CD006320.pub4.

Author Information

  1. 1

    Shaare Zedek Medical Center, Pediatric Gastroenterology Unit, Jerusalem, Israel

  2. 2

    The Hospital for Sick Children, Division of Gastroenterology, Hepatology & Nutrition, Toronto, ON, Canada

*Raffi Lev-Tzion, Pediatric Gastroenterology Unit, Shaare Zedek Medical Center, Jerusalem, Israel. raffilv@szmc.org.il.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 28 FEB 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Omega-3 versus placebo, Outcome 1 Relapse rate at one year (all studies).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Omega-3 versus placebo, Outcome 2 Relapse rate at one year (enteric coated studies).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Omega-3 versus placebo, Outcome 3 Relapse rate at one year (sensitivity analysis of Belluzi 1996).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Omega-3 versus placebo, Outcome 4 Relapse rate at one year (enteric coated - risk difference).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Omega-3 versus placebo, Outcome 5 Relapse rate at one year (sensitivity analysis - excluding abstract study).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Omega-3 versus placebo, Outcome 6 Relapse rate at one year (sensitivity analysis - excluding pediatric study).
[Analysis 1.7]
Analysis 1.7. Comparison 1 Omega-3 versus placebo, Outcome 7 Relapse rate at one year (all studies, rate in EPIC studies by survival estimates).
[Analysis 1.8]
Analysis 1.8. Comparison 1 Omega-3 versus placebo, Outcome 8 Relapse rate at one year (only EPIC studies).
[Analysis 1.9]
Analysis 1.9. Comparison 1 Omega-3 versus placebo, Outcome 9 Relapse at one year, survival analysis (Hazard Ratios of the EPIC studies).
[Analysis 1.10]
Analysis 1.10. Comparison 1 Omega-3 versus placebo, Outcome 10 Adverse events rate: Diarrhea.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Omega-3 versus placebo, Outcome 11 Adverse events rate: Upper GI symptoms (nausea, vomiting, halitosis, heartburn, dyspepsia, disgeusia and bloating).